Confidential PrEP Assessment, Prescription Planning and Follow-Up
PrEP (pre-exposure prophylaxis) is medicine taken by people who do not have HIV to prevent HIV infection before a possible exposure. Correctly used oral and injectable PrEP is highly effective at preventing sexually acquired HIV. It does not prevent chlamydia, gonorrhea, syphilis, herpes, HPV, hepatitis C or pregnancy. A safe PrEP service confirms HIV-negative status, matches the medicine to the exposure route, checks relevant laboratory results and maintains follow-up.
STDtest.clinic supports confidential PrEP enquiries and clinician-led assessment in Dubai, with suitable home or hotel consultation, specimen collection, prescription coordination and medication supply or administration only where the specific activity, prescriber, product and location are authorized. The primary service base is Arjan, Dubai. Patients in Abu Dhabi, Sharjah and elsewhere in the UAE can request an eligibility and service-area check; inter-emirate coverage is not assumed.
Choosing PrEP for your exposure and health needs
Daily oral TDF/FTC is a well-established option for sexual HIV prevention and for people with injection-related HIV exposure risk. A person with new or multiple partners, inconsistent condom use, a recent bacterial STI, or a partner whose HIV viral load is unknown or not suppressed may benefit. Patients can discuss PrEP without having to disclose or prove a particular risk category to a website form.
A partner with HIV who maintains viral suppression does not transmit HIV sexually (U=U). A person without HIV may nevertheless request PrEP for additional reassurance or protection with other partners. PrEP eligibility is discussed respectfully, without assumptions about sexual orientation or relationship status.
PrEP is for prevention before exposure; PEP is the urgent option after certain exposures. A condom break, unprotected sex or another possible HIV exposure within the previous 72 hours needs immediate PEP assessment. Do not wait for PrEP tablets to build protection or for a negative early HIV test. PEP, when indicated, is started as soon as possible and taken for 28 days; subsequent transition to PrEP can be planned.
Oral PrEP medications: generic ingredients, brands and strengths
Truvada and generic TDF/FTC
Truvada contains emtricitabine (FTC) 200 mg plus tenofovir disoproxil fumarate (TDF) 300 mg per tablet. Generic products with the same active ingredients and strengths may also be available. The standard daily regimen is one tablet by mouth once daily, with or without food. TDF/FTC is the oral PrEP formulation identified in the UAE National HIV Management Guideline. A clinician must confirm HIV status, kidney function, hepatitis B status, other medicines and the correct prevention schedule.
TDF and FTC are active against HIV, and both have activity against hepatitis B virus. This makes hepatitis B screening and safe discontinuation important: a person with active hepatitis B may develop a flare if the medicines are stopped without medical monitoring. TDF/FTC is not a complete treatment regimen for established HIV infection.
Descovy and generic TAF/FTC
Descovy contains emtricitabine (FTC) 200 mg plus tenofovir alafenamide (TAF) 25 mg per tablet. Where authorized for PrEP, it is taken once daily. TAF/FTC has different kidney, bone and lipid considerations from TDF/FTC, but it is not indicated for prevention of HIV through receptive vaginal sex, because effectiveness for that exposure has not been established. It should not be presented as a universally interchangeable alternative to Truvada.
TAF/FTC is not automatically the better option for every patient. Baseline renal function, weight, lipid profile, hepatitis B infection, exposure route, drug interactions and local product authorization matter. CDC recommends baseline cholesterol and triglyceride assessment for people starting TAF/FTC PrEP.
What is actually supplied in the UAE?
A generic ingredient name is not a guarantee that a particular brand is stocked, UAE-registered or permitted for PrEP at every clinic. STDtest.clinic should confirm the actual licensed product, packaging, formulation, prescription pathway, dispensing permission, price and delivery arrangements before offering a specific brand as available. The clinic’s medicine-sale authorization does not, by itself, establish eligibility to prescribe every HIV prevention medicine outside the UAE guideline’s HIV-clinic requirements.
How effective is PrEP, and when does it start working?
Daily oral PrEP reduces sexual HIV acquisition risk by approximately 99% when taken as prescribed. It is highly effective but not a guarantee of zero risk. For injection-related HIV exposure, evidence supports a substantial reduction with oral PrEP, though the evidence base and effectiveness estimates differ from those for sex.
For daily oral PrEP, drug concentrations reach levels associated with maximal protection for receptive anal sex after about seven days of daily use. For receptive vaginal sex and injection-drug exposure, CDC describes up to about 21 days of daily dosing. Evidence is insufficient to give one precise onset time for every insertive sexual exposure. These are pharmacologic estimates, not permission to skip individual counselling or local protocol requirements.
The UAE National HIV Management Guideline describes seven days before and seven days after heterosexual exposure for its daily TDF/FTC pathway. This local instruction differs from the CDC’s more conservative time-to-maximal-protection estimate for receptive vaginal exposure. Clinicians must reconcile the patient’s exposure route with current local policy and the evidence, rather than promising that seven days is universally sufficient for every vaginal exposure.
Protection declines after PrEP is stopped. CDC notes that protection from daily oral PrEP wanes over approximately 7–10 days after discontinuation. A planned stop, missed course or switch between medicines should include advice about the last exposure, ongoing risk, hepatitis B status and whether PEP is needed.
Event-driven 2-1-1 PrEP: a limited, off-label option
The 2-1-1 schedule uses TDF 300 mg/FTC 200 mg tablets around anticipated sex: two tablets 2–24 hours before sex, one tablet 24 hours after the first dose and one tablet 48 hours after the first dose. Repeated encounters require an adjusted continuation schedule, so it is not safe to apply the three-dose outline mechanically to every situation.
The UAE National HIV Management Guideline describes on-demand TDF/FTC for men who have sex with men (MSM). CDC describes evidence in adult gay and bisexual men but does not recommend 2-1-1 as its standard PrEP regimen, and it is not FDA-approved. It is not established for receptive vaginal sex, pregnancy-related vaginal exposure or injection-drug HIV prevention. Patients with active hepatitis B should avoid intermittent TDF/FTC because stopping and restarting may cause hepatitis flares.
2-1-1 is not suitable for someone who cannot anticipate sex or reliably follow the timing. It is not a way to treat an exposure that has already happened; urgent PEP assessment may be necessary instead. Any use requires a clinician who is authorized to prescribe it and able to provide appropriate monitoring under UAE requirements.
Injectable PrEP: cabotegravir and lenacapavir
Cabotegravir (Apretude)
Cabotegravir long-acting injection is an integrase inhibitor used for HIV prevention in eligible people without HIV. Apretude is an international brand example. The usual injection formulation is cabotegravir 600 mg/3 mL intramuscularly: an initial injection, a second injection one month later, and maintenance injections every two months. An optional oral lead-in may be used in some protocols to assess tolerability.
Injectable cabotegravir avoids daily tablets and does not require the same routine renal monitoring as tenofovir-based oral PrEP. It requires on-time visits, HIV testing before injections and review of injection-site reactions, drug interactions and possible acute HIV symptoms. If injections are missed or discontinued, residual drug can remain in the body for a prolonged period; the clinician should arrange alternative prevention and HIV testing during this pharmacologic tail.
Lenacapavir (Yeztugo)
Lenacapavir is a capsid inhibitor used as long-acting PrEP by subcutaneous injection every six months after a specific initiation schedule. Yeztugo is a brand example in jurisdictions where authorized. WHO recommended twice-yearly injectable lenacapavir as an additional PrEP choice in July 2025, and CDC issued a US clinical recommendation in 2025 for eligible people weighing at least 35 kg.
The initiation schedule is not simply one injection every six months from day one. It involves product-specific oral and injectable loading doses, followed by maintenance injections. Exact doses, timing, interactions and HIV testing must be checked against the licensed product information and prescribing protocol. Trial efficacy is high, but neither 100% protection nor UAE product availability should be claimed without evidence.
Apretude and Yeztugo are not interchangeable with HIV treatment medicines or with each other. Availability in another country does not establish UAE registration, clinic stock, reimbursement or authorization for home injection. STDtest.clinic should advertise a bookable injectable service only after verifying all of those requirements.
Tests before starting PrEP
HIV infection must be excluded before PrEP is started. A laboratory fourth-generation HIV-1/2 antigen/antibody test is central to baseline assessment; HIV-1 RNA testing may also be required depending on recent exposure, symptoms and prior PrEP/PEP use. Fever, rash, swollen lymph nodes or other symptoms after a recent exposure may signal acute HIV and require a different diagnostic pathway.
An early negative HIV result is not proof that infection is absent. The laboratory fourth-generation test typically has an 18–45-day detection window in people not taking antiretroviral medication, and NAT generally detects HIV around 10–33 days after exposure. Taking PrEP or PEP may delay or alter test interpretation. Ambiguous results require repeat evaluation before PrEP is continued or started.
Kidney assessment is needed before tenofovir-based oral PrEP. CDC specifies estimated creatinine clearance (eCrCl) greater than 60 mL/min for TDF/FTC and at least 30 mL/min for TAF/FTC. Creatinine alone without an appropriate clearance calculation may be insufficient. Renal monitoring frequency increases with age, lower baseline clearance, diabetes, hypertension or other kidney risks.
Hepatitis B screening matters before oral TDF/FTC or TAF/FTC. Testing can include HBsAg, anti-HBs and anti-HBc according to the clinical question. Hepatitis C screening, syphilis serology and chlamydia/gonorrhea testing at relevant genital, rectal or throat sites should be offered according to exposure and local guidance. Pregnancy testing, lipid assessment and other investigations are individualized.
PrEP does not require an indiscriminate laboratory package. The appropriate tests depend on the medicine, route of exposure, symptoms, history, vaccinations and whether there has been recent PEP use.
Monitoring and refills while taking PrEP
PrEP is an ongoing prevention service, not a one-time tablet purchase. HIV testing must be repeated at recommended intervals, adherence and new exposures reviewed, and appropriate STI screening offered. Kidney monitoring is required for oral PrEP according to patient risk and regimen.
CDC recommends HIV antigen/antibody and HIV-1 RNA testing at least every three months for daily oral PrEP users, with prescriptions generally limited to a 90-day supply between HIV tests. The UAE guideline specifies a maximum 12-week prescription at each clinic visit and describes an initial monthly fourth-generation testing phase followed by three-month testing. The actual schedule should follow applicable UAE HIV-clinic protocol and individual clinical circumstances.
For injectable cabotegravir, HIV testing and injection visits follow the initial, month-one and every-two-month schedule. Lenacapavir has its own testing and six-month injection schedule. A patient should not assume that a monitoring plan for one product is valid for another.
A positive or inconclusive HIV test during PrEP requires urgent clinician review. Continuing a prevention-only regimen in someone who has acquired HIV can promote drug resistance. Confirmed HIV infection requires a complete antiretroviral treatment regimen, not PrEP alone.
Missed tablets, vomiting, interruptions and switching PrEP
A missed daily tablet does not automatically mean PrEP has failed, but repeated missed doses can reduce protection. Patients should follow their prescribed product’s missed-dose instructions rather than doubling doses indiscriminately. A clinician should assess whether protection was adequate around any exposure and whether urgent PEP evaluation is needed.
Vomiting soon after a dose, significant diarrhoea or an interrupted supply may require individualized advice. The response depends on timing, the specific medicine and the person’s exposure pattern. A planned transition from PEP to PrEP should avoid an unprotected gap when ongoing risk is present.
Changing from oral to injectable PrEP, or between injectable options, requires a documented transition plan. It includes confirming HIV status, selecting a start date and avoiding gaps or unnecessary overlap. Missed long-acting injection appointments require prompt contact with the prescribing service.
Side effects, interactions and special medical situations
Oral TDF/FTC can cause transient nausea, headache or gastrointestinal symptoms; renal and bone effects are important for selected patients. TAF/FTC may have different renal/bone effects but can be associated with changes in lipids and weight. Cabotegravir commonly causes injection-site discomfort. Lenacapavir can cause injection-site reactions and has clinically important interaction considerations.
Medication interactions should be checked before prescribing. Tenofovir requires particular care with medicines that affect kidney function, including certain high-dose NSAIDs and nephrotoxic agents. Cabotegravir and lenacapavir have important interactions with some enzyme-inducing medicines; a complete prescription, over-the-counter and supplement list is needed.
PrEP is compatible with many hormonal contraceptives, but it is not contraception. Pregnancy intentions, pregnancy and breastfeeding require a regimen-specific discussion. TDF/FTC has substantial experience in pregnancy-related HIV prevention; TAF/FTC should not be substituted for receptive vaginal exposure without appropriate evidence and authorization.
Active hepatitis B is not automatically a reason to deny daily oral PrEP. It does require a clear monitoring and discontinuation plan because abruptly stopping medicines active against HBV may cause liver inflammation. Patients with significant kidney disease may need a non-tenofovir option if available and appropriate.
PrEP, other STIs and comprehensive prevention
PrEP prevents HIV, not other sexually transmitted infections. Chlamydia, gonorrhea and syphilis may have no symptoms, so genital, throat or rectal testing should be selected according to exposure. Condoms, hepatitis A and B vaccination, HPV vaccination, partner communication and routine screening remain relevant.
DoxyPEP is not HIV PrEP or HIV PEP. CDC supports discussing doxycycline post-exposure prophylaxis with selected gay, bisexual and other men who have sex with men and transgender women with a recent bacterial STI. It is not universally indicated and raises antibiotic resistance and tolerability questions. Its use in the UAE requires a separate clinical and regulatory review.
A partner’s sustained undetectable HIV viral load prevents sexual HIV transmission (U=U). PrEP may still be useful for protection involving other partners or for individual reassurance. U=U does not prevent other STIs.
PrEP at home, in hotels and across the UAE
A home PrEP consultation can include risk assessment, medication review, appropriate blood collection, STI swabs and follow-up planning. Where the prescribing pathway is authorized, eligible medication may be prescribed and supplied or dispensed under the applicable permissions. Injection administration at home requires separate verification of the product, setting, trained professional and emergency readiness; it is not promised automatically.
In Dubai, patients may enquire from Arjan, Dubai Marina, JBR, JLT, Palm Jumeirah, Downtown Dubai, Business Bay, DIFC, Jumeirah, Dubai Hills Estate, Emirates Hills, Al Barsha, Arabian Ranches, City Walk and Bluewaters. This is a geographic enquiry list, not a claim of confirmed same-day coverage.
In Abu Dhabi, enquiries may include Saadiyat Island, Al Reem Island, Al Maryah Island, Yas Island, Al Raha Beach, Khalifa City, Al Bateen and the Corniche. In Sharjah, enquiries may include Al Majaz, Al Khan, Al Taawun, Muwaileh and Aljada. Other UAE emirates can request a location and licensing check or a suitable referral. Confirmed appointment availability depends on emirate-specific authorization and staffing.
Confidential care is not the same as anonymous care. Identity checks, prescription records, laboratory reporting and any legal disclosures follow applicable UAE rules. Patients should receive the approved privacy policy and know how results and medication records are handled.
The STDtest.clinic PrEP pathway
- Describe the prevention need. Explain whether you want daily tablets, an injectable option, advice after stopping PrEP, or help after a recent exposure. Mention the last possible HIV exposure and any PEP use.
- Complete the right baseline assessment. HIV testing, renal assessment for oral PrEP, hepatitis status, STI screening and medication review are selected according to clinical need and local guidance.
- Choose an eligible regimen. The clinician discusses TDF/FTC, other authorized oral options and any injectable options actually registered and available in the UAE. On-demand 2-1-1 is considered only within its evidence and local prescribing restrictions.
- Confirm medicine supply and care location. Before payment or booking, confirm the exact generic and brand, strength, prescription authority, medicine availability, dispensing or delivery route, fees and home-visit suitability.
- Maintain protection and follow-up. HIV testing, side-effect review, renal or lipid monitoring where needed, STI screening, refills and safe stopping or switching are planned in advance.
Important clinical and publication notice
PrEP is prescription-only HIV prevention medication. This page is not a self-prescribing guide, a guarantee of medicine availability or a substitute for an HIV-clinic consultation. A possible HIV exposure within 72 hours requires urgent PEP assessment, not a routine PrEP booking. Specific prescribing, dispensing, injection and inter-emirate services are offered only where clinically suitable and explicitly authorized.